Taragenyx announces appointment of Beverley Ouzman as in-house patent counsel

- Former head of AIM listed IP lifescience practice joins Taragenyx -

Glasgow, Scotland - December 02, 2015

Orthopaedic biotechnology company, Taragenyx Ltd., today announced that Beverley Ouzman, has been appointed as the Company’s in-house patent counsel.

Ouzman, the former lifesciences practice head of AIM quoted Murgitroyd & Co. (LSE:MUR), brings recent and direct experience of managing intellectual property portfolios and product licensing transactions across the chemical, lifesciences, and medical devices fields. Her particular areas of professional interest are in the fields of chemistry, biochemistry and biotechnology including immunology, genetics and virology.

“Bev is one of those very rare individuals who not only understand the management of lifescience IP, but who also has experience of what it takes to successfully bring a company onto the public markets,” said Iain McDougall, CEO of Taragenyx. “It’s that unique combination that makes Bev an exceptional patent attorney, and I’m delighted to have her join us as Taragenyx continues to grow.”

Rather than the more traditional client-company relationship, Ouzman will work directly with the Taragenyx team as in-house counsel on a part-time basis. She will manage the Company’s growing patent estate and take the lead on customer licensing transactions.

“I’m very excited about working with the Taragenyx team,” said Ouzman. “They are a young, very forward thinking Company who really like to move fast. It’s not often you see that, especially in lifesciences.”

Ouzman graduated from Oxford University with a degree in biochemistry (with chemical pharmacology a supplementary subject). She then completed a certificate in Intellectual Property law at the University of London. She originally trained with Frank B Dehn & Co (now rebranded as “Dehns”) in London, before moving to Glasgow and joining Murgitroyd & Co, becoming a Director of the company. She remained at Murgitroyd, heading up their Life Sciences team until 2013. After leaving Murgitroyd & Co., Ouzman subsequently founded her own IP company, Ouzman IP.

Taragenyx has pioneered the development of self-healing therapeutic implants aimed at tackling the incredibly painful and expensive problem of orthopaedic implant failure. They are the youngest and only biotech company on the prestigious London Stock Exchange ELITE Program for high growth businesses.